Nexalis Therapeutics Limited (ASX:NX1)

Revenue by Segment

Financials in millions AUD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Development of Unique Medicinal Products	986.43K	401.81K	1.20M	24.80K	181.74K
Development of Unique Medicinal Products Growth	145.50%	-66.63%	4755.02%	-86.35%	721.35%
Total	986.43K	401.81K	1.20M	24.80K	181.74K
Total Growth	145.50%	-66.63%	4755.02%	-86.35%	721.35%

Revenue by Geography

Financials in millions AUD. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Australia	24.80K	167.30K
Australia Growth	-85.18%	1232.33%
Total	24.80K	167.30K
Total Growth	-85.18%	1232.33%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 19, 2026

Data Sources Report a data error